AVXL - Anavex Life Sciences Corp.
Anavex Life Sciences Corp. , a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex.
As of May 15, 2026: spot at $2.92, ATM IV 37.3%, max pain $3.00, net GEX $21.5K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $285.4M
- Beta
- 1.25
- 52-Week Range
- 2.61-13.99
- CEO
- Christopher U. Missling
- Employees
- 42
- IPO Date
- Aug 2, 2006
- Exchange
- NASDAQ
What AVXL Looks Like to Options Traders Today
IV rank of 6.6% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($21.5K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (-0.347) prices puts richer than calls, the typical equity downside-protection skew.
What This Page Covers
The AVXL overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked AVXL overview questions
- What is AVXL?
- AVXL is the ticker symbol for Anavex Life Sciences Corp., a listed security. Anavex Life Sciences Corp. , a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Listed on NASDAQ. AVXL is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the AVXL options snapshot look like today?
- As of May 15, 2026, the AVXL options snapshot shows spot at $2.92, ATM IV 37.3%, IV rank 6.6%, max pain $3.00, net GEX $21.5K, expected move 10.69%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are AVXL's key statistics?
- Anavex Life Sciences Corp. (AVXL) carries a market capitalization of $285.4M, beta of 1.25 relative to the broader market, 52-week range of 2.61-13.99. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does AVXL belong to?
- Anavex Life Sciences Corp. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare AVXL's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the AVXL data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).